Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2012. The report details a specific share repurchase transaction executed on March 12, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 400,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,428.5 pence per share; lowest price paid was 1,419.5 pence per share.
- Treasury Holdings (Settled): 511,697,927 shares (9.21% of total issued share capital).
- Treasury Holdings (Including Unsettled): 512,997,927 shares (10.17% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,045,664,761 shares.
Material Changes
The material change reported is the reduction of outstanding shares through the purchase of 400,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.17% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (511,697,927 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.17% held in Treasury including unsettled shares) for disclosure threshold assessments.
- Check the price paid per share (1,419.5 to 1,428.5 pence) against market trading data for March 12, 2012.
- Note that this filing does not contain financial performance data; refer to Form 20-F for comprehensive financial results.